Marleen Melis
Feb 1, 2007
Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs
Müller C, Forrer F, Bernard B, Melis M, Konijnenberg M, Krenning E, de Jong M. Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs. Cancer Biother Radiopharm 2007; 22:151-9.
Feb 1, 2007Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs
Feb 1, 2007Cancer Biother Radiopharm 2007; 22:151-9
Müller Cristina, Forrer Flavio, Bernard Bert F, Melis Marleen, Konijnenberg Mark, Krenning Eric P, de Jong Marion
more
Feb 1, 2007
From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging
Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, Krenning E, de Jong M. From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging. Cancer Biother Radiopharm 2007; 22:40-9.
Feb 1, 2007From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging
Feb 1, 2007Cancer Biother Radiopharm 2007; 22:40-9
Forrer Flavio, Rolleman Edgar, Bijster Magda, Melis Marleen, Bernard Bert, Krenning Eric P, de Jong Marion
more